H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on C4 Therapeutics to $7 from $17 and keeps a Buy rating on the shares. The analyst dropped the price target to reflect the company’s pipeline reprioritization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics reports Q3 EPS (55c), consensus (66c)
- C4 Therapeutics announces upcoming data on Phase 1/2 trial of CFT7455, CFT8634
- C4 Therapeutics price target lowered to $2 from $5 at BofA
- ImmunoGen names Lauren White as CFO